Camp4 Therapeutics Corp
Close on Oct 19, 2026
- Market cap
- $181.90M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $795.00K | $-0.55 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 27, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 21, 2024 | During market hours | – | – | – |
Press releases
Announcements Camp4 Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01
Regulation FD disclosure · EX-99.1 to Form 8-K
CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Material agreement · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Haploinsufficient SYNGAP1 mice treated with CMP-SYNGAP-01 demonstrated an increase in SYNGAP1 protein levels; treatment rescued multiple SYNGAP1-dependent behavioral phenotypes
Regulation FD disclosure · EX-99.1 to Form 8-K
Pioneering a new class of RNA medicines to increase targeted gene expression May 2025 C O R P O R A T E O V E R V I E W
Regulation FD disclosure · EX-99.2 to Form 8-K
CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Pioneering a new class of RNA medicines to increase targeted gene expression Corporate Overview January 2025
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CAMP4 Provides Corporate Updates and Highlights
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
CAMP4 Reports Third Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K